Investor Relations

Investor Relations

Latest News

View All News

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Read Press Release

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Read Press Release

Upcoming Event

2024 Annual Meeting of Stockholders

Latest Financial Results

Earnings Release

Earnings Webcast

10-K Filing

XBRL

Company Information

OPKO Health is a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets. Led by an accomplished management team whose drug development experience is unmatched in the industry and partnered with other leading pharmaceutical companies, OPKO Health is dedicated to advancing proven technologies to transform patients’ lives.

At OPKO Health, we’ve developed and delivered new medicines that are marketed throughout the world. With our focus on harnessing next-generation solutions by pioneering new advances on proven technologies, our approved therapies are positioned to offer better treatment options for patients.

We believe the future of medicine will be multispecific. Our research efforts are focused on advancing multispecific therapies that have the potential to treat the multifaceted drivers of serious conditions including cancers and infectious disease. Our R&D team is comprised of the former leaders of N.I.H., Sanofi and other leading scientific organizations and our programs have attracted partnerships with Pfizer, Merck, CSL Vifor, N.I.H., and BARDA.

As one of the largest full-service clinical reference laboratories in the U.S., serving approximately 11 million patients annually, BioReference Laboratories is a leading diagnostics company that continues to deliver innovations for patients and physicians, particularly those working in specialty areas.

IR Contacts

Company

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137
T: 305-575-4100
contact@opko.com

Investor Relations

LHA
Yvonne K. Briggs
T: 310-691-7100
YBriggs@lhai.com

LHA
Bruce Voss
T: 310-691-7100
bvoss@lhai.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11209
T: 718-921-8317
https://www.amstock.com

Connect With Us